This is Part II of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.
This is Part I of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.
Cancer drug sales are slowing down in the U.S., Reuters reported Monday.
In a study of 19 patients with glioblastoma, progression-free survival increased from 6 months to 19 months.
Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space, recent advancements and study results are encouraging.
The 160,000 square-foot facility could bring at least 300 jobs to Georgia.
Researchers found that Dendreon’s immunotherapy drug Provenge prolonged the lives of advanced prostate cancer patients by an average of 4.1 months compared to a placebo.
Copyright © 2025 | WordPress Theme by MH Themes